KROS
Keros Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +8.3% ·
share flow -0.4% ·
net new positions +7.7%
— formula
Ownership fragmentation — more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 68 | -2 | 12.51M | $133.89M | +5 | −7 |
| Q1 2026 | 72 | +4 | 12.53M | $138.59M | +8 | −4 |
| Q4 2025 | 68 | +1 | 14.80M | $301.38M | +1 | — |
| Q3 2025 | 16 | 0 | 12.05M | $190.67M | — | — |
| Q2 2025 | 13 | +1 | 9.42M | $125.76M | +2 | −1 |
| Q1 2025 | 9 | -1 | 3.92M | $39.99M | +1 | −2 |
| Q4 2024 | 10 | 0 | 4.67M | $74.00M | +1 | −1 |
| Q3 2024 | 9 | -1 | 4.72M | $274.14M | +1 | −2 |
| Q2 2024 | 10 | — | 3.52M | $160.87M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 2.73M | — | $36.48M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | BlackRock ✦ (passive) | 2.73M | — | $36.48M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | BlackRock ✦ (passive) | 2.73M | — | $36.48M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | BlackRock ✦ (passive) | 2.73M | — | $36.48M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | BlackRock ✦ (passive) | 2.73M | — | $36.48M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | BlackRock ✦ (passive) | 2.73M | — | $36.48M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | BlackRock ✦ (passive) | 2.73M | — | $36.48M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | BlackRock ✦ (passive) | 2.73M | — | $36.48M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | BlackRock ✦ (passive) | 2.73M | — | $36.48M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | The Vanguard Group ✦ (passive) | 2.63M | — | $35.13M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | The Vanguard Group ✦ (passive) | 2.63M | — | $35.13M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | The Vanguard Group ✦ (passive) | 2.63M | — | $35.13M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | The Vanguard Group ✦ (passive) | 2.63M | — | $35.13M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | State Street Global Advisors ✦ (passive) | 1.38M | +6.3% | $18.48M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 15 | D. E. Shaw & Co. ✦ | 1.30M | +2.7% | $17.32M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 16 | Geode Capital Management ✦ (passive) | 829.30K | +2.9% | $11.07M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 17 | Geode Capital Management ✦ (passive) | 829.30K | +2.9% | $11.07M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 18 | Fidelity (FMR) ✦ | 164.27K | — | $2.19M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | Fidelity (FMR) ✦ | 164.27K | — | $2.19M | 0.0% | n/c | 1 | SEC ↗ |
| 20 | Renaissance Technologies ✦ | 146.60K | New | $1.96M | 0.0% | New | 1 | SEC ↗ |
| 21 | AQR Capital Management ✦ | 70.65K | +219.2% | $943,179 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 22 | AQR Capital Management ✦ | 70.65K | +219.2% | $943,179 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 23 | AQR Capital Management ✦ | 70.65K | +219.2% | $943,179 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 24 | AQR Capital Management ✦ | 70.65K | +219.2% | $943,179 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 25 | AQR Capital Management ✦ | 70.65K | +219.2% | $943,179 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 26 | Arrowstreet Capital ✦ | 64.58K | New | $862,156 | 0.0% | New | 1 | SEC ↗ |
| 27 | T. Rowe Price ✦ | 48.41K | +12.0% | $647,000 | 0.0% | ▲ Add | 5 | SEC ↗ |
| 28 | Citadel Advisors ✦ | 22.90K | -88.0% | $305,688 | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 29 | Citadel Advisors ✦ | 22.90K | -88.0% | $305,688 | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 30 | Millennium Management ✦ | 13.71K | -94.1% | $182,962 | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 31 | Two Sigma Investments ✦ | 13.52K | -78.3% | $180,519 | 0.0% | ▼ Trim | 5 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Renaissance Technologies | $1.96M | 0.0% |
| Arrowstreet Capital | $862,156 | 0.0% |
Exited
| Point72 Asset Management | $59 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 149 holders, 18.56M shares, $201.20M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Director · 1.00K sh @ 10.27 · $10,270
Open-market sales (S)
Officer · 4.49K sh · $46,151
Director · 551 sh · $5,675
Officer · 3.57K sh · $36,715
Officer · 1.22K sh · $12,595
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology